Sotorasib,adagrasib,Cetuximab,Afatinib,Pembrolizumab,JDQ443,tislelizumab,GDC-6036,alectinib,Atezolizumab,gemcitabine,Entrectinib,Cobimetinib,Vemurafenib,bevacizumab,Adagrasib,Docetaxel
Amgen,mirati,Eli Lilly,Boehringer Ingelheim,Merck,Novartis,Beigene,Roche,Daiichi Sankyo,Sanofi,Aventis,Novartis
[]
excellent summary on kras inhibitors from including the trials and resistance mechanisms #esmo22 
Medical Oncologist, Translational Researcher, Peter Mac. Tweets are my own opinions. Musician (@mayhemtomi) https://t.co/f3ccD2Ml7v